These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 22902995)
1. Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor. Jung KH; Zheng HM; Jeong Y; Choi MJ; Lee H; Hong SW; Lee HS; Son MK; Lee S; Hong S; Hong SS Cancer Lett; 2013 Jan; 328(1):176-87. PubMed ID: 22902995 [TBL] [Abstract][Full Text] [Related]
2. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway. Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943 [TBL] [Abstract][Full Text] [Related]
3. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer. Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694 [TBL] [Abstract][Full Text] [Related]
4. Induction of apoptosis and suppression of angiogenesis of hepatocellular carcinoma by HS-159, a novel phosphatidylinositol 3-kinase inhibitor. Yun SM; Lee JH; Jung KH; Lee H; Lee S; Hong S; Hong SS Int J Oncol; 2013 Jul; 43(1):201-9. PubMed ID: 23604199 [TBL] [Abstract][Full Text] [Related]
5. A novel imidazopyridine derivative, HS-106, induces apoptosis of breast cancer cells and represses angiogenesis by targeting the PI3K/mTOR pathway. Li GY; Jung KH; Lee H; Son MK; Seo J; Hong SW; Jeong Y; Hong S; Hong SS Cancer Lett; 2013 Feb; 329(1):59-67. PubMed ID: 23085493 [TBL] [Abstract][Full Text] [Related]
6. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364 [TBL] [Abstract][Full Text] [Related]
7. IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma. Lee JH; Lee H; Yun SM; Jung KH; Jeong Y; Yan HH; Hong S; Hong SS Cancer Lett; 2013 Feb; 329(1):99-108. PubMed ID: 23142281 [TBL] [Abstract][Full Text] [Related]
8. Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines. Masuda M; Shimomura M; Kobayashi K; Kojima S; Nakatsura T Oncol Rep; 2011 Nov; 26(5):1273-9. PubMed ID: 21725613 [TBL] [Abstract][Full Text] [Related]
9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925 [TBL] [Abstract][Full Text] [Related]
10. HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis. Lee H; Jung KH; Jeong Y; Hong S; Hong SS Cancer Lett; 2013 Jan; 328(1):152-9. PubMed ID: 22929971 [TBL] [Abstract][Full Text] [Related]
11. Anti-cancer effects of a novel compound HS-113 on cell growth, apoptosis, and angiogenesis in human hepatocellular carcinoma cells. Choi MJ; Jung KH; Kim D; Lee H; Zheng HM; Park BH; Hong SW; Kim MH; Hong S; Hong SS Cancer Lett; 2011 Jul; 306(2):190-6. PubMed ID: 21463918 [TBL] [Abstract][Full Text] [Related]
12. Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis. Zeng KW; Li N; Dong X; Ma ZZ; Jiang Y; Jin HW; Tu PF Eur J Pharmacol; 2013 Aug; 714(1-3):261-73. PubMed ID: 23684542 [TBL] [Abstract][Full Text] [Related]
13. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Chang KY; Tsai SY; Wu CM; Yen CJ; Chuang BF; Chang JY Clin Cancer Res; 2011 Nov; 17(22):7116-26. PubMed ID: 21976531 [TBL] [Abstract][Full Text] [Related]
14. Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway. He L; Wu Y; Lin L; Wang J; Wu Y; Chen Y; Yi Z; Liu M; Pang X Cancer Sci; 2011 Jan; 102(1):219-25. PubMed ID: 21087351 [TBL] [Abstract][Full Text] [Related]
15. The effect of HS-111, a novel thiazolamine derivative, on apoptosis and angiogenesis of hepatocellular carcinoma cells. Choi MJ; Lee H; Lee JH; Jung KH; Kim D; Hong S; Hong SS Arch Pharm Res; 2012 Mar; 35(4):747-54. PubMed ID: 22553069 [TBL] [Abstract][Full Text] [Related]
16. Apoptotic and anti-angiogenic effects of Pulsatilla koreana extract on hepatocellular carcinoma. Hong SW; Jung KH; Lee HS; Choi MJ; Zheng HM; Son MK; Lee GY; Hong SS Int J Oncol; 2012 Feb; 40(2):452-60. PubMed ID: 21935571 [TBL] [Abstract][Full Text] [Related]
17. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway. Hong SW; Jung KH; Lee HS; Choi MJ; Son MK; Zheng HM; Hong SS Cancer Sci; 2012 Nov; 103(11):1929-37. PubMed ID: 22909393 [TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling. Huang SW; Lien JC; Kuo SC; Huang TF Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611 [TBL] [Abstract][Full Text] [Related]
19. Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling. Man K; Ng KT; Xu A; Cheng Q; Lo CM; Xiao JW; Sun BS; Lim ZX; Cheung JS; Wu EX; Sun CK; Poon RT; Fan ST Clin Cancer Res; 2010 Feb; 16(3):967-77. PubMed ID: 20103676 [TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. Chan SL; Wong CH; Lau CP; Zhou Q; Hui CW; Lui VW; Ma BB; Chan AT; Yeo W Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]